

How registries can help tackle the global diabetes burden

Online event

1 October 2024 14:30-16:00 CEST





WELCOME FROM THE MODERATOR



DR HERMELINDA PEDROSA

IDF Vice President Physician, Chair of IDF Women and Diabetes Committee, International Relations Advisor and Advocacy at SBD (Brazilian Diabetes Society), Coordinator at the Endocrinology Unit Research Centre HRT/FEPECS, Investigator at Fiocruz Biomanguinhos

Brasil

WELCOME FROM IDF

- This webinar will be recorded.
- You can activate Zoom-generated subtitles for this webinar by clicking on the closed caption (cc) button at the bottom of your Zoom window. Please note these subtitles are not 100% accurate.
- The recording, slides and feedback questionnaire will be sent to all registrants in a few days.
- Participants who attend at least 80% of this event live will receive an attendance certificate only if they
 complete a feedback questionnaire. Please check your spam folders if you have not received them <u>by 20</u>
 <u>October.</u>
- Please use the Q&A function to post your questions to speakers and panellists.

Setting the scene





MESSAGE FROM THE IDF PRESIDENT



PROF PETER SCHWARZ

IDF President, Research group leader at the Paul Langerhans Institute Dresden (PLID)

Germany



REAL-WORLD EVIDENCE THE NEXT GENERATION OF CLINICAL EVIDENCE



PROF KAMLESH KHUNTI

Professor of Primary Care Diabetes & Vascular Medicine at the University of Leicester, iCaReMe Steering Committee Member

United Kingdom



EXPERIENCE IN IMPLEMENTING A NATIONAL DIABETES REGISTRY IN PAKISTAN



PROF ABDUL BASIT

Secretary General of the Diabetic Association of Pakistan (DAP), President of the Diabetes in Asia Study Group (DASG), and Vice Chairman at the Health Promotion Foundation (HPF).

Pakistan




How did it start?

2010 Insulin My Life



Centers established

Subjects registered



34


1900 +

Comparison of abnormal HbA1c levels (according to age) from baseline to last visit

Ahmedani MY, et al. Optimized health care for subjects with type 1 diabetes in a recourse constraint society; A three-year follow-up study from Pakistan. World Journal fo Diabetes 2019;15:10:224

2019 Prevalence of T2DM and Associated Risk Markers

1 in 5 persons aged 20 and above have diabetes



33 million people with diabetes in Pakistan

	2021		2030		2045	
Rank	Country or Territory	Adults with diabetes, (million)	Country or territory	Adults with diabetes, (million)	Country or territory	Adults with diabetes, (million)
1	China	140.9	China	164.1	China	174.4
2	India	74.2	India	92.9	India	124.9
3	Pakistan	33.0	Pakistan	42.9	Pakistan	62.0
4	United States of America	23.7	United States of America	34.8	United States of America	36.3
5	Indonesia	19.5	Indonesia	23.3	Indonesia	28.6
6	Brazil	15.7	Brazil	19.2	Brazil	23.2
7	Mexico	14.1	Mexico	17.1	Bangladesh	22.3
8	Bangladesh	13.1	Bangladesh	16.1	Mexico	21.2
9	Japan	11.0	Egypt	13.8	Egypt	20.0
10	Egypt	10.9	Turkey	10.8	Turkey	13.4

IDF Diabetes Atlas 10th edition updates, Available from:

https://diabetesatlas.org/data/en/country/150/pk.html (Last accessed on November 12, 2021)



Aims and Objective of DROP

Incidence and prevalence

National action plan and prevention policy

Structured and uniform clinical care

Implementation of National Guidelines

Specific post graduate teachings; Preventive managers

Policy making and legislation

Linking with Regions; e.g. DASG and IDF-MENA Region



How did it progress?



Stakeholders for DROP

Ministry of National Health Services Regulations and Coordination

National Institute of Health

Health – Research Advisory Board (Health RAB)

Health Promotion Foundation (HPF)

Diabetic Association of Pakistan (DAP)













National Bioethics Committee (NBC) Approved



National Institutes of Health Health Research Institute National Bioethics Committee (NBC)



Ref: No.4-87/NBC-782/22/2325

Date: June 16, 2022

Prof. Abdul Basit Baqai Institute of Diabetology and Endocrinology and Diabetic Association of Pakistan Plot No. 1-2, II-B, Nazimabad No2 Karachi

Subject: Diabetes Registry of Pakistan (DROP) (NBC-782).

Dear Prof. Abdul Basit

I am pleased to inform you that the above mentioned project has been approved by the "Research Ethics Committee" of "National Bioethics Committee" for a period of one year.

For the continuation of project in the next years, you have to send a progress report and a formal request asking for continuation of projects (however, you do not need to submit REC application or pay any processing fee again).

Kindly keep the National Bioethics Committee, Secretariat updated about the progress of the project and submit the formal final report on completion.

Yours sincerely Joury (Prof. Dr. Saima Perwaiz Iqbal) Chairperson NBC-Research Ethics Committee

Health Research Institute, Shahrah-e-Jamhuriat, Off Constitution Avenue, Sector G-5/2, Islamabad www.nbcpakistan.org.pk.e-mail: nbcpakistan@nih.org.pk Tel: 92-51-9224325, 9216793, Fax 9216774.

Advocacy

Sindh Health Department – BIDE

Ô

Health and Population Welfare Department, Sindh ② @Sind... 1h ···· Karachi (18-06-21): MoU signed b/w Baqai Institute of Diabetology, Diabetic Association of Pakistan & Sindh Health Department for the standardisation of diabetic treatment in all healthcare facilities. Minister for Health & Secretary Health oversaw the signing #SindhHealth



- Primary prevention
- Diabetes Awareness
- Diabetes Registry of Pakistan(DROP)
- Conduct diabetes research

18th June 2021

Meeting with DDG Sindh for standardization of diabetes care in rural health centers of Sindh

Training Programs in rural and urban areas of Sindh

> Murad Memon Goth, Matiari with Sindh Governement





MoU

Advocacy



- Primary prevention
- Diabetes Awareness
- Diabetes Registry of Pakistan(DROP)
- Conduct diabetes research
 - 26th November 2020



Meeting with CEO & COO of PPHI for standardization of diabetes care in PPHI HF






CDiC Centers – Pakistan





How do we see its future?



Barriers and Solutions

• Initiate the process and governments get involved.

• Capacity building.

• Minimal Model registries to make it time-effective.

- Adequate anonymization increases healthcare personnel's confidence and decreases the sense of insecurity.
- Private-public partnerships with cross-financing models ensure sustainability
- Implementation and surveillance gets stronger with government involvement. Bodies like WHO play a key role in its facilitation.

IDF has selected our DROP registry as an example for Diabetes Epidemiology **LMICs** Studies

National Institutions



Liaquat national Institute of PG Med & Health Sciences, Karachi



Diabetic Association of Pakistan (DAP



Sobhraj Maternity Hospital



The Karachi Institute of Biotechnology and Genetic Engineering (KIBGE)



University of Karachi (KU)



Jinnah Sindh Medical University, karachi (JSMU)



Fatima Jinnah Medical College, Lahore



Dow University of Health Sciences (DUHS)



King Edward Medical University, Lahore



Jinnah University for Women (JUW)

Bolan Medical

College, Quetta





National Institute of Diabetes & Endocrinology (NIDE)



Khyber Medical University, Peshawar



Liaquat Univeristy of Medicine and Health Sciences, Hyderabad




Pakistan Endocrine Society (PES)




PG Medical Institute, Hayatabad medical Complex, Peshawar



Rana Liaquat Ali Khan Government College of Home Economics (RLAK)









FROM DATA TO ACTION: THE ROLE OF FACILITY-BASED MONITORING IN DIABETES CONTROL




PROF FARSHAD FARZADFAR

Scientist, NCD department, WHO, HQ

Switzerland

NCD surveillance system components





Noncommunicable disease facility-based guidance: scope and development process

- Comprehensive monitoring for essential noncommunicable disease interventions at primary care settings
 - Cardiovascular diseases including hypertension
 - o Diabetes
 - Asthma and chronic obstructive pulmonary disease
 - Breast cancer, cervical cancer, childhood cancers and general cancers
- Rigorous development and prioritization processes (experts' opinions, systematic reviews, global and regional priorities)



Facility-based patient and program monitoring framework

НҮ	PERTENSION AND CARDIOVASCULAR DISE	ASES
INPUTS/PROCESSES System capacity and management	OUTPUTS Early detection and diagnosis	OUTCOMES Disease control
 Availability of hypertension core medicines Availability of cardiovascular disease core medicines Availability of a functional blood pressure measuring device 	 Assessment of cardiovascular disease risk (aged ≥40 years) Screening for hypertension among adults as part of routine service Hypertension detection from opportunistic screening Complication assessment Assessment for chronic kidney disease among people newly diagnosed with hypertension 	 Blood pressure control among people with hypertension Blood pressure control among people with hypertension (follow-up)
	DIABETES	
INPUTS/PROCESSES	OUTPUTS	OUTCOMES
System capacity and management	Treatment	Disease control
 Availability of diabetes core medicines Availability of plasma glucose testing Availability of Hemoglobin A1c testing 	 Pharmacological treatment among people with diabetes Statin therapy among people with diabetes Pharmacological treatment for chronic kidney disease among people with diabetes Pharmacological treatment for hypertension among people with diabetes Complication assessment Assessment for diabetic chronic kidney disease among people with diabetes Assessment for diabetic foot among people with diabetes Assessment for diabetic foot among people with diabetes Referral for retinopathy screening among people with diabetes 	 Glycaemic control among people with diabeter Glycaemic control among people with diabeter (follow-up) Chronic kidney disease among people with diabetes Lower-limb amputation among people with diabetes Blindness among people with diabetes

How registries can help tackle the global diabetes burden

.000.

Indicator metadata

C2-Availability of plasma glucose testing

Indicator name	Availability of plasma glucose testing
Purpose	To ensure uninterrupted services to diagnose diabetes and assess glycemic control among patients with diabetes

- Definition Proportion of health facilities that have capability of laboratory or point of care plasma glucose (PG) testing
- Numerator Number of health facilities reporting capability of performing either laboratory or point of care PG tests in the reporting period

Denominator Total number of health facilities

Method of Numerator ÷ denominator × 100 calculation

Aggregation District, province, state, national

- Disaggregation Health facility, provider ownership type (public/private), facility location type (urban/rural), plasma glucose testing site (point-of-care or laboratory)
- Sources of data Health facility reports, regional logistics information system or survey
- Key data elements Count of number of facilities reporting "test capability"

Frequency of Quarterly reporting

- Users of data District-, province- and state-level managers to focus supervision on health facilities reporting no lab capability, making facilities capable and strengthening health systems to ensure uninterrupted laboratory services
- Limitations/ In some settings the health facilities do not provide laboratory services comments so the reporting units will need to come from other laboratory service providers
- Related links Harmonized health facility assessment (HHFA): core questions https://www.who.int/publications/i/item/harmonized-health-facilityassessment-(hhfa)

- Definition, purpose, numerator, denominator, calculation method, aggregation, disaggregation, sources of data, key data elements, frequency of reporting, users of data, limitations/comments and related links
- Comparability of data across geographical areas and across times

Digital Data Collection tool (NCD DHIS2)

Back + F I NO	CD patient monitoring form	x v	
ndicators			v 0
eedback			v 0
rimeline Data Entry			I≣ ~ 0
abular Data Entry			0100
Hypertension - Initial	Date of visit •		+
visit	2024-02-01		
Hypertension - Follow- up visit	Hypertension - Follow-up visit		
	Date of visit	2024-02-01	
	SBP (mmHg)	130	
	DBP (mmgHg)	80	
	Diagnosed with CVD	⊖ Yes ⊗ No	
	High-risk CVD	Yes	× -
	Prescribed treatment for hypertension?	⊘Yes ⊖No	
	Thiazide and thiazide-like agents		
	Dosage (number and unit)	12.5 mg	
	Dosage (frequency per day)	daily	
	Angiotensin-converting enzyme inhibitors		
	Angiotensin-receptor blockers		
	- Long-acting dihydropyridine calcium channel blockers		
	Date of follow-up visit	2024-05-01	
	Complete	Dei	Print form

ofile Edit					<u>^ 1</u>	
Unique ID						
Given name	Marta	Marta				
Middle name						
Family name	Mercado					
Sex at birth	Female				× -	
Date of birth known	O Yes 🛞 No					
Age – estimated	1981-03-04	Years 43	Months 0	Days 1	Û	
Mother's maiden name (Given name viddle name Family name)	Jane Mercado					
Father's name (Given name Middle name Family name)	Marlon Mercaod					
Current address – village and district	[Please select]				Đ	
Current address – details	Rue de Lyon 75					
Same as permanent address	⊘ Yes O No					
Permanent address – village and district	[Please select]					
Permanent address – details	Rue de Lyon 75					
Contact phone number	0772421800					
Email address	marta@y.com					
Asthma programme enrolment						
COPD programme enrolment						
Diabetes programme enrolment	f you added a new disease to the patient, please remember to save your changes by clicking the blue save button below. If not please ignore this warning.					
Hypertension programme enrolment						
Cervical cancer screening and treatment	~					
Clinical breast evaluation for early diagnosis of breast cancer						
Clinical evaluation for early diagnosis of other cancers	If you added a new d the blue save button	lisease to the patient, below. If not please ig	please remember to a nore this warning.	save your changes by	clicking _X	

Cardiovascular Disease Risk Scoring

Individual Calculation					^
Manual Data Entry Fetch from DHIS	22				
Parameters					
What is the patient's country of resid	ence?		How old is the patient	t?	
Ghana		⊗ ∽	55	⊗ -	+
What is the patient sex?	Does the patient smoke?		Is the patient diabetion	c?	
🔾 Female 💿 Male	● No 🦳 Yes		O No ○ Yes		
What is the patient's systolic blood p	ressure in mmHg? What is	the patient	's total cholesterol in r	nmol/L?	
180.00	⊗ - + 5.50			⊗ -	+
Ca	alculate the 10-Year Risk of	a CVD Eve	ent		
Result					
10-Year Risk of a CVD Event					
10%					



WHO - CVD Risk Calculator

This tool is based on World Health Organization cardiovascular disease risk charts: revised models to estimate risk in **21 global regions** published in the *Lancet Global Health*.

Individual Calculation Manual Data Entry Fetch from DHIS2	Laboratory-Based	Non-Laboratory-Based	
Manual Data Entry Fetch from DHIS2	Individual Calculat	ion	
	Manual Data Entry	Fetch from DHIS2	

Parameters

What is the patient's country of residence?
How old is the patient?

Select a country
40 to 74 Years

What is the patient sex?
Does the patient smoke?

Is the patient diabetic?
Is the patient diabetic?

Female
No<Yes</td>

What is the patient's systolic blood pressure in mmHg?

10 to 300 mmHg

What is the patient's total cholesterol in mmol/L?

Calculate the 10-Year Risk of a CVD Event

Batch Calculation

Data Upload

Upload patients dataset in CSV (.csv) or Excel (.xlsx , .xls) format. For download of the template Excel file for laboratory-based CVD risk calculation, *click here*.


Drag and drop file here
 Limit 200MB per file • CSV, XLSX, XLS


Browse files


^

^

Universal NCD Dashboard and Action Plan Developer









Indicator Values Value of Patient-Level Indicators with the Previous Report	⊥ Export			
INDICATOR	FACILITY	DISTRICT	PROVINCE	NATIONAL
BRCC1	77.5	80.0	80.6	75.0
Breast Cancer C1	(~*2.9%)	(~*2.8%)	(~*2.9%)	(~*2.7%)
BRCC2	100.0	94.1	91.2	84.8
Breast Cancer C2	(~*2.6%)	(~*2.7%)	(~*2.9%)	(~*2.7%)
CHCC1	70.8	59.0	50.3	46.8
Childhood Cancers C1	(~*2.8%)	(~2.9%)	(~³3.1%)	(~≈2.9%)
CHCC2	100.0	96.7	91.2	84.8
Childhood Cancers C2	(~*2.2%)	(~3.6%)	(~³3.1%)	(~*2.9%)
CRDC3	46.0	35.2	39.3	36.5

(~2.1%)

Chronic Respiratory Diseases C3

CRDC4

(~2.7%)


(~2.9%)

801

(~*2.7%)

82

Facility-based monitoring stream work





THANK YOU

farzadfarf@who.int



ASPECTS AND ANECDOTES AROUND A TYPE 1 DIABETES REGISTRY




DIANA NOVELO ALZINA

YLD Mentor and Council's Treasurer of the Diabetes Association of Southeastern Mexico (Asociación Mexicana de Diabetes en el Sureste)

Mexico

A TYPE 1 DIABETES REGISTRY

- A YLD project that joined forces with the National movement <u>"One Voice in Type 1 Diabetes"</u> for a national type 1 diabetes registry in Mexico.
 Movement's logo:
- The intention of a national registry:
- ☆ Reach the maximum goal → complete access to treatment
- \diamond Obtain statistical data \rightarrow advocate for policies that improve the quality of care
- ♦ Appel for Budget → a government budget specific for T1D
- ♦ Assert rights to health → better care, fewer complications, more lives saved.



3. Impulsar un registro nacional de personas con diabetes tipo 1



COMMENTS BASED ON: THE REGISTRY OF PEOPLE LIVING WITH TYPE 1 DIABETES IN THE STATE OF YUCATAN, MEXICO.





THANK YOU

Discussion panel and Q&A







CLOSING REMARKS AND THANKS



DR HERMELINDA PEDROSA

IDF Vice President Physician, Chair of IDF Women and Diabetes Committee, International Relations Advisor and Advocacy at SBD (Brazilian Diabetes Society), Coordinator at the Endocrinology Unit Research Centre HRT/FEPECS, Investigator at Fiocruz Biomanguinhos

Brasil

CLOSING REMARKS AND THANKS

• The recording, slides and feedback questionnaire will be sent to all registrants in a few days.

- Please respond to the feedback questionnaire to help us improve future IDF online events.
- Send any questions you may have to <u>advocacy@idf.org</u> or <u>atlas@idf.org</u>



Sign up for the IDF newsletter



Shape the future of diabetes



IDF World Diabetes Congress

Bangkok, Thailand, 7 – 10 April 2025

Why attend

Key date

• **31 Oct 2024** Early rate deadline

- 10 programme streams
- 130 hours of scientific sessions
- **250** international speakers



THANK YOU